Reformulation into Long-Acting Injectables and Implants

Long-acting, drug delivery products based on PLG-parenteral functional excipients have been used to reformulate and repurpose more than 60 drugs. This white paper reviews the conversion of oral and immediate-release injectable formulations into long-acting injectable microparticle and implant formulations. Such reformulation and repurposing strategies will continue to be used to achieve superior long-acting systemic and local delivery outcomes over the coming decade. This trend will be further accelerated by the combination of highly potent drugs with long-acting formulations to reduce injection volumes and extend the period of drug release.

 

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.